Congenital Pericardial Anomalies

Saremi, Farhood

doi:10.1007/978-1-4614-8875-0_29

Cited by 3 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients received a non-ionic low-osmolality contrast agent (iodixanol; GE Healthcare Life Sciences, Chalfont, UK), with a volume of 30–120 mL (1–1.5 mL/kg) and flow injection rate of 3–5 mL/s, followed by saline injection administered intravenously using a power injector at same volume and velocity. 5 A bolus triggering was used to scan initiation. The scans were acquired with a 70–120 kV of tube voltage with an automatic tube current modulation technique (CAREdose).…”

Section: Methodsmentioning

confidence: 99%

“… 4 Therefore, a high diagnostic suspicion is required to refer children and adolescents to invasive and ionising examinations (CT or angiography). 5 In this context, echocardiography has always been considered the method of screening and diagnosis with the most limited accuracy. However, this examination is the first-line test recommended and prescribed by physicians when a congenital cardiac abnormality is suspected.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Echocardiographic screening for the anomalous aortic origin of coronary arteries

et al. 2021

View full text Add to dashboard Cite

AimsWe sought to determine the diagnostic performance, clinical profiles and outcomes of anomalous aortic origin of coronary arteries (AAOCA) using a standardised echocardiographic approach in young adults and athletes.MethodsIn 2015–2019, we screened 5998 outpatients (age 16 years (Q1–Q3: 11, 36)), referred for routine echocardiography, using four specific echocardiographic windows: parasternal short/long axis and apical 4/5-chambers view. Coronary CT confirmed AAOCA. For the performance analysis, 300 coronary-CT scans were available; two independent and double-blinded physicians retrospectively reviewed echocardiographic images.ResultsA total of 47 AAOCA was diagnosed; the overall prevalence was 0.0078%. Over 5 years, we found a significant increment of AAOCA diagnostic rate (P for trend=0.002). Syncope (n=17/47) and palpitations (n=6/47) were prevalent symptoms. All patients suspended sports activity at the diagnosis. Twenty-seven patients underwent surgery, while 20 underwent a conservative medical treatment. All patients are alive at a median follow-up of 3±1.6 years; only surgical repairs restarted their activity. Our method showed better sensitivity than traditional short-axis evaluation: 93% vs 83%, p=0.0030 (AUC 0.96 (95% CI 0.92, 0.99) and AUC 0.89 (95% CI 0.83, 0.95), respectively), with a good interobserver agreement (95%, k=0.83, p<0.001).ConclusionsThe application of a standardised echocardiographic approach for AAOCA detection led to a significantly increased rate of identified anomalies. This approach demonstrated higher sensitivity than the traditional echocardiographic assessment. Implementing this protocol in clinical practice may help improve the AAOCA diagnosis in young adults and athletes.Trial registration numberNCT04224090.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Echocardiographic screening for the anomalous aortic origin of coronary arteries

et al. 2021

View full text Add to dashboard Cite

show abstract

“…1). 2,23,24 Regarding atrial and ventricular septal defects, echocardiography is mostly sufficient in neonates and pediatrics, and to date remains the best noninvasive tool to estimate pulmonary artery systolic pressure. On the contrary, CMR's cine images permit a precise quantification of the volumes and function of the dilated right/left-sided…”

Section: Cardiovascular Magnetic Resonance and Cardiovascular Compute...mentioning

confidence: 99%

“…CMR can describe each pulmonary vein in anomalous connections, reveal obstruction, quantify left-to-right shunting and describe associated lesions and relevant implications for patient management. 24,50 Venous pathway assessment is also a crucial component of transposition of the great arteries (TGA) treated by atrial switch operation. Systemic and/or pulmonary baffle complications are common in this typical adult population and may be inadequately imaged by echocardiography.…”

Section: Systemic and Pulmonary Veinsmentioning

confidence: 99%

Recommendations for cardiovascular magnetic resonance and computed tomography in congenital heart disease: a consensus paper from the CMR/CCT Working Group of the Italian Society of Pediatric Cardiology and the Italian College of Cardiac Radiology endorsed by the Italian Society of Medical and Interventional Radiology (Part II)

Festa,

Lovato,

Bianco

et al. 2024

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

Cardiovascular magnetic resonance (CMR) and computed tomography (CCT) are advanced imaging modalities that recently revolutionized the conventional diagnostic approach to congenital heart diseases (CHD), supporting echocardiography and often replacing cardiac catheterization. This is the second of two complementary documents, endorsed by experts from the Working Group of the Italian Society of Pediatric Cardiology and the Italian College of Cardiac Radiology of the Italian Society of Medical and Interventional Radiology, aimed at giving updated indications on the appropriate use of CMR and CCT in different clinical CHD settings, in both pediatrics and adults. In this article, support is also given to radiologists, pediatricians, cardiologists, and cardiac surgeons for indications and appropriateness criteria for CMR and CCT in the most referred CHD, following the proposed new criteria presented and discussed in the first document. This second document also examines the impact of devices and prostheses for CMR and CCT in CHD and additionally presents some indications for CMR and CCT exams when sedation or narcosis is needed.

show abstract

“…Atherogenesis is a sequence of events associated with the expression of adhesion molecules, , recruitment of mononuclear cells to the endothelium, local activation of leukocytes followed by inflammation, lipid accumulation, and foam cell formation . The main predilection sites of manifestation of the atherosclerotic pathology are the deep intimal layers of large arteries such as the common carotid artery (at the bifurcation), the aorta (at the start of its branches), and the subclavian artery …”

mentioning

confidence: 99%

Lectin-like Oxidized Low-Density Lipoprotein (LDL) Receptor (LOX-1): A Chameleon Receptor for Oxidized LDL

2016

View full text Add to dashboard Cite

LOX-1, one of the main receptors for oxLDL, is found mainly on the surface of endothelial cells. It is a multifacet 52 kDa type II transmembrane protein that structurally belongs to the C-type lectin family. It exists with short intracellular N-terminal and long extracellular C-terminal hydrophilic domains separated by a hydrophobic domain of 26 amino acids. LOX-1 acts like a bifunctional receptor either showing pro-atherogenicity by activating the NFκB-mediated down signaling cascade for gene activation of pro-inflammatory molecules or playing an atheroprotective agent by receptor-mediated uptake of oxLDL in the presence of an anti-inflammatory molecule like IL-10. Mildly, moderately, and highly oxidized LDL show their characteristic features upon LOX-1 activation and its ligand binding indenture. The polymorphic LOX-1 genes are intensively associated with increased susceptibility to myocardial diseases. The splicing variant LOX IN dimerizes with the native form of LOX-1 and protects cells from damage by oxidized LDL. In the developing field of regenerating medicine, LOX-1 is a potential target for therapeutic intervention.

show abstract

Congenital Pericardial Anomalies

Cited by 3 publications

References 32 publications

Echocardiographic screening for the anomalous aortic origin of coronary arteries

Echocardiographic screening for the anomalous aortic origin of coronary arteries

Lectin-like Oxidized Low-Density Lipoprotein (LDL) Receptor (LOX-1): A Chameleon Receptor for Oxidized LDL

Contact Info

Product

Resources

About